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Abstract
Molecular Analysis of Oligoclonal T cells Associated with Graft-Versus-Host Disease
Following Allogeneic Stem-cell Transplantation

By Kassi M. Avent

A dissertation submitted in partial fulfillment of the requirements for the degree of Master’s of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2012
Director: Masoud Manjili, DVM, PhD
Professor of Microbiology and Immunology
The goal of hematopoietic stem cell transplantation (HSCT) is to induce graft-versus-tumor
effect (GVT), which is the recognition of and response against tumor- associated antigens (TAAs) by
donor immune cells to clear the recipient of residual tumor. A complication of HSCT as a treatment
for hematologic malignancies is graft-versus-host disease (GVHD), which is the recognition and
reactivity of donor immune cells against healthy tissues. As of now, the differentiation between
GVHD and GVT effects has been a hindrance to the development of effective therapies against
GVHD. Certain T cell clones may induce both GVHD and GVT effects, making targeted therapy of
GVHD difficult. This project was aimed to uncover differences at a molecular level of the T cell
recognition site that exist between patients with GVHD and those with GVHD-free survival
following allogeneic HSCT. We found that there are inherent differences in the T cell receptor at a
molecular level between patients experiencing GVHD and those that are GVHD-free, suggesting the
ability of T cells to distinguish tumor cells from self cells. In addition, the intention was to reveal
differences in proportions of engrafted donor T cells and stem cells and the effects of these
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proportions on the severity, outcome, and prognosis of GVHD. We additionally found that a lower
proportion of stem cells to T cells was associated with the trend of GVHD, while a higher frequency
of T cells engrafted into host may indicate resistance to treatment and a poor prognosis. These data
suggest that allogeneic HSCT may be improved by optimizing the proportion of T cells to stem cells
in the transplant as well as developing targeted therapy against GVHD-associated T cell clones while
rescuing GVT-associated T cell clones.

x

Introduction

Hematopoietic Stem Cell Transplantation

Hematopoietic stem cell transplantation (HSCT) is used in the treatment of hematological
disorders as a curative therapy and works by the intravenous infusion of healthy donor cells in order to
replace diseased host hematopoietic cells following their T cell depletion.1 An added benefit of the use
of HSCT in the treatment of blood cancer patients is graft- versus- tumor effect (GVT), which is the
involvement of donor T cell recognition of tumor antigen in the immune response against blood cancer.
However, the success of HSCT is limited by the onset of graft-versus-host disease (GVHD).

Graft-versus-host Disease

Graft- versus- host disease in this study is the result of donor T cells recognizing minor
histocompatibility antigens (mHAs) presented by human leukocyte antigens (HLA) on host tissue and
mounting a destructive response against them.2,3 It can be lethal, and is therefore of paramount concern
when considering HSCT as a treatment option.4 Recognition of host cells by donor’s T cells is HLAdependant, which occur when a T cell recognizes and mounts an immune response to a foreign HLA
molecule or nonself mHA presented by a self HLA molecule.3,5 Donors and recipients must be matched
in HLAs in order to reduce the risk of GVHD. Therefore, HSCT is ideally conducted with donors that
match recipients in at least five major HLAs (1 paternal and 1 maternal allele for each of the five HLAs
matched), and allogeneic GVHD reaction must be beyond HLA mismatch. 3,6 This means that the
recognition of host HLA by donor T cells is an unlikely method of GVHD induction. Antigenic peptides

presented in the context of HLA, i.e. mHAs, on the other hand, are polymorphic protein products that
may mismatch between HLA- matched donor and recipients, resulting in alloreactivity upon
transplantation.2,7 Some mHAs are ubiquitously expressed on all tissue, whereas others are expressed
primarily on hematopoietic cells.3 Antigens that are expressed ubiquitously are prime targets for GVHD,
whereas those that are restricted to the hematopoietic system are more likely to function in GVT. 3,6 In
addition, mHAs that are encoded by the Y chromosome (H-Y antigens) may result in GVHD or GVT
reactivity in male recipients of female stem cells.5 The importance of mHAs is emphasized when
considering that tumor cells are constantly undergoing immunoediting to rid themselves of highly
immunogenic tumor associated antigens (TAA’s).8 The significance of mHAs is demonstrated in the
observation that patients with HLA-matched unrelated donors are still more likely to develop GVHD
than patients with HLA-matched related donors.4
The conditioning regimen for preparation of HSCT in the host involves the use of a T cellspecific antibody (Thymoglobulin® {ATG}, in this particular study) that specifically targets the
thymocytes of the recipient and initiates their destruction.6 This results in the removal of host T- cells
from circulation, as ATG targets multiple markers specific to T cells.6 This treatment is designed to
remove diseased host cells while allowing room within the host microenvironment for the growth and
proliferation of donor cells, but also prevents recipient cells from mounting a counterattack against the
donor cells once they have responded to healthy recipient tissue. This is designed so that recipient cells
cannot cause rejection of the transplant.1,4,6
GVHD occurs due to a combination of factors unique to the transplant setting. Primarily, the
recipient is immunocompromised due to myoablative (via radiation) and/or lymphoablative (via
chemotherapy and/or antibodies directed at lymphocytes) conditioning prior to donor cell introduction,
in combination with the introduction of immunocompetent immune cells from donor that the host is
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unable to reject.9 Since antigens recognized by donor immune cells may not be specific to tumor alone,
GVT in many cases occurs in conjunction with GVHD.8 However, hematolymphoid cells are most
susceptible to alloreactive T cells, thus, expression of tumor-specific antigens or tissue-restricted
antigens on malignant cells may cause GVT reactivity without the co-occurrence of GVHD.8 It is
therefore imperative to distinguish the minute, yet key differences in the recognition regions of immune
cells that can allow for the differentiation of tumor versus healthy host tissue. Previous studies both in
our lab and elsewhere have uncovered key Vβ families associated with both GVHD and GVT utilizing
q-RT PCR, but so far a molecular exploration of amino acid sequences of the antigen-recognition site of
the T cell receptor (TCR) have been insufficient. 10,11,12

The T cell Receptor
T cells are part of the adaptive immune response that play a major role in GVHD. In GVHD, T
cells rely on differences in mHAs between donor and recipient that are matched in five major HLAs.
This is demonstrated by the abolishment of both GVHD and GVT effects when T cells are depleted
from the transplant or the donor is an identical twin.8 Host antigens such as mHA are presented to donor
T cells in the context of HLA by host antigen-presenting cells (APC’s) that induce donor-derived T cell
proliferation and differentiation during GVHD or GVT effects. 7,13
The T cell receptor (TCR) is a heterodimer made up of two chains, an alpha (α) and a beta (β)
chain, linked by a disulfide bond and each with both a variable and a constant region. 5,14 The constant
region links the TCR to the T cell via a positively charged transmembrane region.5 The variable region
of the α chain contains a variable (V) and a junctional (J) gene segment and the variable region of the β
chain also contains both the V and the J genes, with the addition of a diversity (D) gene segment in
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between the two.5,14 These are the gene segments that rearrange to form the full TCR variable domain.
The variable regions of the α and β chains align to form the antigen- recognition and binding site, and
each TCR has one binding site. The TCR recognizes antigen bound to a major histocompatibility
complex (MHC) molecule presented to it by an APC.5 The MHC gene in humans encodes HLA, for
human leukocyte antigen, and the TCR must recognize and bind both antigen and HLA in conjunction in
order for activation of the T cell to occur (a phenomenon called MHC restriction). 3,5 There are over 200
HLA genes on the human chromosome 6, which produce a multitude of genes, 40 of which encode
leukocyte antigens. HLA’s are divided into groups that fall into a three classes.2 Class I and class II
HLA’s are of importance to this study because they have the potential to induce an immune reaction if
not matched between donor and host properly.3 From these two classes the five HLA’s that are matched
between donor and recipient can be found. In HLA class I, HLA-A, HLA-B, and HLA-C and in HLA
class II HLA-DRB1 and HLA-DQB1 are matched between donor and recipient in HSCT. These five
HLAs are selected due to their high diversity amongst individuals, and therefore high potential for
alloreactivity if not properly matched. The nomenclature of class II genes derives from letters
designating information on the gene that it encodes. The first letter (D) designates the class, the second
the family (M, O, P, Q, R), and the final letter, the HLA chain in which it belongs (α or β).2 Numbers
preceding an asterisk following the HLA name indicate the gene and numbers following the asterisk
indicate the individual allele of which a particular HLA belongs.2 For example, HLA-DQB1*0301
belongs to HLA-D class II gene, is in the Q family on the beta chain, and is 0301 allelic variant of gene
1.2 Class I HLA’s are expressed on the surface of almost all somatic cells of our body (with exception of
enucleated cells like red blood cells) while class II HLA’s are present on the surface of hematopoietic
antigen presenting cells. 2,3,5 This key difference in HLA location stems from the activity that each cell
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needs to induce in the T cell that they are presenting to. Antigen presented on a class I gene signals to
CD8+ T cells, while antigen presented on a class II gene signals to CD4+ T cells.2,5
There are three hypervariable loops in both the α and β chains known as complementarity
determining regions (CDR) that make up the variable region of the TCR. The first two, CDR1 and
CDR2, are contained entirely within the V gene, whereas CDR3 is made up of the combinations of the
V, D, and J genes. The CDR3 is responsible for the antigen-recognition portion of the T cell: HLA
complex. This is the region in which most of the diversity of the TCR is concentrated due to the method
in which the TCR is generated.5 While all three CDR’s allow for specificity of the peptide:MHC
(pMHC) complex, it is the highly diverse CDR3 region that is responsible for antigen specificity.5,15 T
cells can be distinguished by their unique CDR3 region, and it is for these reasons that this particular
region is studied so extensively in immune profiling.15

TCR β chain rearrangement

The β chain of the developing T cell undergoes a consecutive, stepwise rearrangement of its
genome that ensures a high amount of diversity within the T cell repertoire. The Vβ gene is located on
chromosome 7 and is organized with the 52 V segments (part of 30 Vβ gene families) preceding two
clusters that each contains one D and multiple J segments.5,16 Alternative splicing of V genes in addition
to genetic polymorphisms in the V, D, and J genes provides a greater diversity than the initial 30 V
genes would confer in addition to the 2 D and 13 J genes. 5,16,17 An enzyme complex called
recombination-activating genes (RAG) that recognize signals (recombination signal sequences, RSS) at
the ends of each region and join one V, D, and J end-on- end in a process called somatic
recombination.5,14 These recombination signal sequences allow for very precise joining of each gene
5

segment.14 At the junction points (between V and D and between D and J), random nucleotide insertions
and subtractions contribute diversity of CDR3 region, which is formed at the junction site of these
genes. An enzyme called terminal deoxyncleotidyl transferase (TdT) is responsible for this process
during the joining of each segment to another. The D and the J segments join one another first, followed
by the joining of the DJ segment to the V segment, and the joining of the entire VDJ region to the
constant region. 5 Following somatic recombination events, each complete Vβ exon will have one V, D,
and J region.5,14 These genes rearrange during thymic development.5 This process generates diversity in
a number of ways. Firstly, the number of different gene segments allows for a multitude of different
potential combinations, leading to what is known as combinatorial diversity. A second type of
combinatorial diversity is the result of the potential of various combinations of a variety of Vβ and Vα’s.
Finally, junctional diversity arises from the addition and subtraction of nucleotides at junction sites as
part of the recombination process.5
Upon successful recombination of a complete β chain, signals to the T cell halt β chain
rearrangement so that only one allele is expressed and all others are silenced (allelic exclusion).This
works by the expression of a pre-T cell receptor, which induces the phosphorylation and subsequent
degradation of RAG acting on the β chain.5 Successful rearrangement of the β chain also induces cell
proliferation.5 After the cells have undergone numerous divisions, the α chain rearranges, leading to a
single β chain being associated with a large number of different α chains. At this point of both the α and
the β chains rearranged and expressed, positive and negative selection can begin.5 After a selected T cell
has been released into the periphery, stimulation by contact with a pMHC complex induces mass
proliferation of the particular T cell specific to the stimulating antigen. For this reason, a skewed
depiction of a particular VJ recombination on a T cell is indicative of an antigen-specific response. 15,18
The use of spectratyping to derive information on skewed clonality is imperative in uncovering VJ
6

recombinations that are upregulated during a disease state. The spectraype methodology works by
displaying each of the V genes in correspondence with the 13 J genes that it can be paired with. An
increase in one VJ recombination at the expense of the others within a V gene will be depicted as a peak
in the graph. This skewed mono- or oligo-clonality is indicative of an antigen- specific response and in
contrast to healthy individuals who have a diverse repertoire of VJ recombinations (polyclonality). 19

Maturation and Proliferation of T cells

Although T cell progenitors are derived from the bone marrow, T cell lymphopoiesis and
maturation occur in the thymus. Multipotent hematopoietic progenitor cells migrate to the thymus via
the blood where they then begin maturation into T lymphocytes. The thymus is the site for the genetic
recombinations that give rise to the billions of different T cells capable of recognizing and responding to
different epitopes (antigenic determinants).5 The thymus is also responsible for both positive and
negative selection of T cells which leads to a large majority of T cells (96-98%) that are eliminated from
the repertoire due to strong reactivity to self, or inability to recognize MHC. Thymic cell signaling is
necessary for both parts of this selection. In positive selection, only those thymocytes (developing T
cells) that bind to thymic MHC molecules, and therefore have the potential to recognize antigen being
presented on them, are given the survival signal needed to continue on by those thymic cells.
Thymocytes that do not bind MHC do not receive this survival signal and undergo “death by neglect”.
5,20

In fact, MHC restriction is determined by positive selection. In negative selection, thymocytes that

recognize host cells with high affinity for pMHC are given a signal to undergo apoptosis due to
overstimulation. These two selective processes are critical in eliminating T cells that have the potential
to recognize and attack host cells, and leads to central tolerance.5 In normal circumstances, the
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presentation of a non-harmful stimulus in the periphery in the absence of co-stimulation (the “second
signal”) that denotes a harmful antigen, the potentially reactive cell undergoes anergy, in order to induce
peripheral tolerance.5 In the stem-cell transplant environment, inflammation from chemotherapy and/or
pre-HSCT treatment regimens can induce expression of co-stimulatory molecules. This can lead to
overcoming this peripheral tolerance process and the activation of T cells against potentially nonharmful stimuli.5
The thymus begins to deteriorate with age, and the critical ability of selection of T cells gradually
diminishes. Thymic activity peaks in infancy, and begins its gradual decline after one year of age.21,22
After middle age, the thymus shrinks by about 1% annually.23 By the age of 60, thymic function is
drastically reduced, and additionally loses its ability to rebound from damage.24,25,26 Thymic epithelium,
which is critical for positive and negative selection of developing T cells, is gradually converted to
adipose tissue.25 Thymic function still allows for the development of new T cells, albeit at a much
slower rate as age progresses.25 All that being said, involution of the thymus produces no noticeable
adverse affects in the healthy aging adult, and only becomes an issue in situations of severe T cell
depletion, such as HSCT treatment, chemotherapy, or AIDS.25 In addition, some pre-treatment regimens
such as chemotherapy for patients undergoing HSCT can damage the thymus, further reducing its
abilities and altering the balance between negative and positive selection, allowing more reactive cells
through the thymus into circulation, in conjunction with GVHD, which initiates further thymic
destruction in the host due to donor T cell attack of the thymic epithelium.8,20 In essence, the thymus
gradually loses its ability to eliminate all self- reactive T cells from the repertoire during negative
selection. These alterations in selection may reduce the ability of T cells in aged individuals to fight
infections and cancer. Therefore, in young adults, thymopoiesis is the most common route for the
generation of peripheral T cells, whereas with age, proliferation of existing T cells must be utilized to
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maintain T cell numbers, in combination with potentially thymus- independent mechanisms to allow
maturation of T cells.21,24 Early after HSCT, before the damaged thymus has had an opportunity to
reconstitute T cells, T cell numbers must be maintained by division of mature donor T cells if few new T
cells are being produced.11,21 The likelihood of the utilization of peripheral expansion as opposed to
thymopoiesis as a route to replace depleted T cell populations in HSCT patients grows increasingly
higher with age and thymic damage associated with treatment, although small amounts of thymopoiesis
are still possible.21,24,25 Studies have shown that both expansion of donor- derived T cells and the
generation of new T cells are both present following HSCT, however, the generation of new T cells
generally takes time associated with the regain of thymic function in conjunction with the slow
replacement associated with old age. 11,24,27,28 Thymic reconstitution in an aged adult following HSCT
may take years.21 In addition, T cells take longer than other cell populations such as B cells and natural
killer cells to recover from lymphopenia.11,21 In a transplant setting, stem cells are mobilized in the
donor prior to removal for transplant, and are therefore also transplanted into recipient with T cells. In
this event, the thymus is less effective in assisting the development of T cells from this stem cell
subset.22,24 Since all the patients considered in this study are well past adolescence (the youngest patient
being 44 years old), development of donor stem cells into T cells occurs very slowly. 21 Restoration of a
normal TCR repertoire can take years to re-establish following lymphodepletion. 11
Two factors that could assist with the reconstitution of thymic function and therefore new T cell
generation following transplant are inductive cytokines and the generation of more room for growth of
new T cells in the recipient microenvironment, in addition to the potential of the existence of an
extrathymic compartment for the maturation of T cells from CD34+ stem cells.31 Although HSCT
conditioning treatments and GVHD both cause thymic destruction, they also induce an increase in
cytokines, some of which may help to boost thymic activity (interleukin-7).25,29,30
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Extrathymic development of T cells is another potential route for the regeneration of the T cell
population in adults, but has not yet been definitively demonstrated in aged adults as a major contributor
to T cell reconstitution following lymphodepletion.2,31 It has been shown in mice, however, that
engrafted thymocytes can go on to develop into lymphocytes in the lymph nodes of irradiated athymic
recipients in mice.32 In addition, these athymic mice can reject allogenic cancer cells. 33 Extrathymic
development has been demonstrated in children who have undergone HSCT as well as in healthy
adults.31,34, 35 Extrathymic T cells are inherently different than thymic T cells in that they react more
readily to antigen encounter (in terms of proliferation rate and cytokine secretion) but also have a faster
turnover due to increased susceptibility to apoptosis.36,37 Extrathymic T cells have been shown to
undergo the elevated homeostatic proliferation necessary for a rebound from lymphodepletion. 31,34,38,39
Finally, studies have shown that autoreactive extrathymic T cells of the innate immune system (such as
those found in GVHD) are more likely to be activated during events of thymic atrophy, such as HSCT
conditioning and GVHD. 40,41

Materials and Methods
Patients
As shown in Table 1, thirteen patients with hematological malignancies who underwent
hematopoetic stem cell transplantation (HSCT) were included in this study. From those patients, four
had non-hodgkin’s Lymphoma (NHL) (patients 3, 7, 9, and 13), four had multiple myeloma (MM)
(patients 4, 11, 12, and 14), three had chronic lymphocytic leukemia (CLL) (patients 5, 6, and 24) and
two had prolymphocytic leukemia (PLL) (patients 8 and 16). Peripheral blood stem cells were collected
from the donor (after stem cell- mobilization followed by apheresis) in order to provide a baseline
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sample following engraftment and full donor T cell chimerism (percentage T cells within recipient that
originate from donor T cells) in recipient. Recipient whole blood samples were collected both prior to
(“R” sample) and at different timepoints following HSCT (R2, R3, R4). As shown in Table 2, in patients
that did not have the complication of GVHD, the R2 sample was taken three months following
transplant and the R3 sample was taken a year following transplant. In the GVHD group, however, R2
or R3 represents the time of clinical manifestation of GVHD. In patient 5, 6, and 9 GVHD was also 3
months following transplant, whereas in patients 11, 13, 14, and 24, GVHD manifested earlier, and the
samples were taken 2 months following transplant. R3 samples were at 3 months for GVHD patients 11,
13, and 14, four months for patients 8, 9, and 24, and at 5 months for patient 6 (patient 5 deceased prior
to an R3 sample). A sample at timepoint R4 was obtained for patient 6 (8 months following HSCT),
patient 9 (1 year), patient 13 (6 months), and patient 14 (6 months).

Representative Patient Selection
From the 13 patients for which high- throughput data was available, four representative patients
were selected for analysis: two that had clinical GVHD symptoms and two GVHD- free patients. The
GVHD and GVHD- free patient groups were divided into two subsets in order to get the most diverse
range of patient variability as possible. From the GVHD group one patient was selected that
demonstrated persistent GVHD following treatment (patient 14) and a second that had GVHD which
resolved after treatment (patient 9) (Table 2). From the GVHD-free group one patient was chosen that
had full chimerism of the donor’s T cells (patient 3) and one that did not have full chimerism at the R2
timepoint (delayed full chimerism) (patient 4). All GVHD patients had approximately full donor T cell
chimerism (Table 3). All samples that were utilized for analysis were sequenced with over 95%
productivity (9R2 sample was eliminated due to low productivity) (Table 4). Patient 9 had no HLA
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mismatches with the respective donor whereas patients 14 and 3 both had one mismatch, and patient 4
had four HLA mismatches with their respective donors (Table 1). Patients were analyzed in pairs so that
each GVHD patient was analyzed with each GVHD-free patient, resulting in four GVHD-GVHD-free
pair groups.
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Table 1. Patient characteristics

Patient

Age/
sex

disease

prior
autologous
HSCT

disease
status
at
HSCT

Donor
age/
sex

Donor

Donors non-identical
HLA alleles

Recipients non-identical
HLA alleles

class I

class II

class I

class II

URD

none

none

none

none

A- 0101, B0801,4402,
Cw-0501,
07WTR

DQB10301, 0302
DRB401ZDV
DRB302AMCC

5
58/M

No

CR

36/M

68/M

CLL

No

CR

63/M

MRD

A01CZRH,
B08DDHN,
44DDHW

57/M

PLL

No

CR

40/M

URD

none

BRB302CYUC

none

9

55/M

NHL

Yes

CR

65/F

URD

none

none

none

11

58/F

MM

Yes

PR

70/M

MRD

Cw-0304

13

59/F

NHL

No

CR

22/M

URD

B-44HTH

14
24
3

56/M
58/M

MM
CLL

Yes
No

PR
PR

43/F
47/F

URD
URD

B-5601
none

44/F

NHL

No

CR

32/M

URD

none

6
8

GVHD

CLL

DQB10302
none
none
DQB10503

Cw- 0302

none
DRB10201, 0301,
DRB301USC,
DRB401ZDV

B-440201

DQB1-0301

B-15GYF
none

none
none

none

GVHD- free

4

none

none

DQB102GM
DQB10301

DQB10201,
DRB302CYUC,
DRB401ZDV

none

DQB1-0302

B07ANVB

none

B- 070201

none

none

DQB10202, 0602,
DRB401ADH,
DRB5-0101

46/F

MM

Yes

PR

52/F

MRD

none

7

56/F

NHL

No

CR

46/F

URD

12

62/M

MM

Yes

PR

20/M

URD

16

62/M

PLL

No

CR

65/M

MRD

none

CLL: chronic lymphocytic leukemia; PLL: prolymphocytic leukemia; MM: multiple myeloma; NHL:
non-Hodgkin lymphoma; PR: partial response; CR: complete response; MRD: matched related donor;
MUD: matched unrelated donor; URD: unrelated donor
13

Table 2. GVHD patient progression
Patient
number disease

R2

R3

5 - CLL

aGVHD delayed onset:
persistent, IV (3 mo);
skin grade 2-3
progressed to GI grade
4

deceased 7/5/2009
(day 162)

No GVHD (3 mo.)

acute; grade 4 gut
aGVHD (5 mo)
7/14/09 (late onset,
IV)

6 - CLL

R4

Gut GVHD was
resolved at 8 mo
but chronic
cutaneous GVHD
(1 y)

cGVHD: 9/30/2010
deceased
10/25/2011 (979
days after SCT)
Deceased
4/27/2010 (404
days after SCT)
GVH resolved at 1
year

No GVHD (3 mo)

GVHD (4 mo)

GVHD resolved
(6-8 mo)

9 - NHL

No GVHD (3 mo.)

cGVHD (4 mo) skin

GVH resolved
(1 y)

cGVHD (3 mo.); skin
GVHD resolved b/w
4 and 6 mo after R3

cGVHD (1 y)

aGVHD grade I (2 mo)
(3/18/2010).; acute
classical skin grade 1;
delayed onset
persistent grade III

delayed onset
aGVHD progressive
(3 mo), skin

GVHD resolved
(6 mo)
(6/10/2010)

14 - MM

cGVHD (2 mo); chronic
skin

3 mo.5/20/2010
GVHD developed on
6/17/10

24 -CLL

aGVHD skin grade 14/27/2011 acute gut
7/12/2011

day 100 (6/7/11);
esophagus GVHD
(6/14/11); colon grade
I to II (6/15/11)

13 - NHL

cGVHD (2 mo.); GVH skin

current status

died of infection

8 - PLL

11 - MM

R5

death cause
unknown,
assumed to be
sepsis
death due to
multi organ
failure post
hemolytic
anemia and
splenectomy

alive
lung and mouth
GVHD
alive in CR
1 year (1/18/2011)
GVHD resolved
alive in CR

(6/22/2010.); skin
and rectal GVHD
aGVHD delayed
onset (4 mo)
6/24/2010: gut
GVH

deceased day 171
DOD: 8/3/2010
(6 mo)

death due to
infection- steroid
refractory GVHD

ISP taper,
remission

CLL: chronic lymphocytic leukemia; PLL: prolymphocytic leukemia; MM: multiple myeloma; NHL: nonHodgkin lymphoma; PR: partial response; CR: complete response; MRD: matched related donor; MUD:
matched unrelated donor. Roman numerals indicate GVHD classification.
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Table 3. Recipient donor T cell chimerism

T cell chimerism
(months after SCT)

GVHD-free

GVHD

Patient
R2

R3

R4

5

0% (3)

Deceased day 162

6

0% (3)

0% (5)

0% (12)

8

1.6% (3)

2.5% (4)

6.4% (12)

9

2.2% (3)

1.6% (4)

0% (12)

11

0% (2)

0% (3)

0% (12)

13

0% (2)

0% (3)

0% (5)

14

0% (2)

1.5% (3)

0%(4)

24

0% (3)

N/A

N/A

3

10.9% (4)

0% (13)

N/A

4

51.3% (3)

8% (11)

N/A

7

51.5% (3)

62.9% (10)

N/A

12

8.6% (3)

0% (12)

N/A

16

4.7% (3)

29.8% (6)

N/A

Percentages indicate the proportion of T cells that are not from the engrafted donor T cells (recipient T cells).
N/A: not available
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Table 4. Percent of productive sequences for each sample analyzed

GVHD

Patients
D

R2

R3
NS

R4
NS

5

97.967

98.837

6
8

96.89

100

98.359

97.242

96.975

99.587

98.513

NS

9

95.909

24.324

97.918

98.08

11

97.755

97.055

97.023

NS

13

96.469

97.874

NS

98.445

14

96.795

97.716

98.185

98.442

24

96.559

98.308

98.812

NS

97.831

97.593

98.734

4

97.237

93.459

96.128

7

97.554

98.558

98.307

12

90.995

98.209

97.867

16

96.397

96.319

NS

GVHD-free

3

NS
NS
NS
NS
NS

NS: No sample sent for analysis
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T cell isolation and mRNA extraction
Recipient samples (R2-R4) were obtained at the aforementioned timepoints and RNA was
extracted as previously described by our group.10 Following a 1:1 dilution in salt solution (1X HBSS),
recipient samples were layered on Ficoll-PaqueTM premium (GE Healthcare) to create a density gradient
upon centrifugation (according to the manufacturer’s protocol). Following centrifugation, the buffy coat
containing mononuclear cells was isolated, washed, and incubated for 2 hours at 37ºC 5% CO2 with
0.1% autolougous serum and RPMI medium. Following incubation, non- adherent cells (lymphocytes)
were collected and CD3+ cells isolated using EasyStep® Negative Selection Human T cell enrichment
Kit according to the manufacturer’s protocol (Stem Cell Technologies).
The procedure for CD3+ isolation differed for donor samples due to the nature of extraction
efficiency for CD34+ cells. It was determined previously that high yields of CD3+ cells could be
obtained from unfractionated CD34+ donor stem cells from peripheral blood following stem cell
mobilization using granulocyte colony- stimulating factor (G-SCF) and apheresis.10 For this reason, the
T cell enrichment kit was not used for donor samples, and samples were cultured in serum- free medium
for two hours and RNA was extracted from non-adherant cells as discussed above.
RNA was extracted from isolated CD3+ stem cells using Trizol (Invitrogen) according to
manufacturer’s protocol. To eliminate contamination of RNA sample with DNA, DNase treatment was
applied using RQ1 RNase-free DNase (Promega, according to manufacturer’s protocol). Superscript II
reverse transcriptase (Invitrogen) was then used to create double- stranded complementary DNA
(cDNA) by incubating 1µg of the total RNA extracted with a dT18 oligonucleotide primer to
specifically amplify polyadenylated mRNA. Synthesis of cDNA was accomplished by incubating for 2
hours at 42ºC in a thermocycler. To confirm purity of samples prior to high- throughput analysis, RNA-
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derived cDNAs were subjected to PCR analysis of GAPDH. The PCR products were then run on 1%
agarose gel. A bright, clear band indicated a pure product with minimal degradation.

High throughput sequencing of TCR Vβ
Upon confirmation of pure product, 1- 119ug (average of 55ug) per sample of cDNA (depending
on how much mRNA was initially extracted) was sent to ImmunoSEQ (Seattle,WA) for high-throughput
molecular analysis of the CDR3 region. The deep- level analysis provided by ImmunoSEQ is capable of
uncovering approximately 8,000,000 sequences per sample (targeted output).42 By utilizing 52 forward
primers for the Vβ gene segment and 15 reverse primers for the Jβ segment, the multiplex PCR system
is able to capture an entire VDJ recombination.43 The primers are designed to accommodate a 60 base
pair read, and since an average CDR3 region is around 35 base pairs, this technique includes most
known CDR3 regions. 42,43 There are, however, rare cases in which very long or very short CDR3
regions are not captured. 42
ImmunoSEQ utilizes a Genome Analyzer (GA) system as a platform for the sequencing that is
conducted. The GA system works by hybridizing the template molecules (with a universal PCR adapter
added) to a lawn of primers that are anchored to a stable base. Following hybridization, PCR amplifies
the cDNA, forming clusters consisting of millions of replications of the template molecules that can then
be sequenced.42 Sequencing is done by the subsequent and repeated incorporation of fluorescent
nucleotides followed by imaging of the nucleotide that is incorporated after each round of addition. The
fluorescence is indicative of which nucleotide was incorporated at each step. This cycle is repeated until
the entire molecule is sequenced. Figure 1 demonstrates how this process works while Figure 2
demonstrates how sequencing is conducted.44 All samples were normalized for PCR bias, which
accommodates for a select few V and J primers that amplify more or less efficiently than others.
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Figure 1. Genome Analyzer system44
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Figure 2. The process of high-throughput sequencing44
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Generation of spectratyping graphs
Clonality data was derived from spectratyping graphs generated from TCR VJ recombination
analysis obtained from ImmunoSEQ in the following manner: From ImmunoSEQ website
(www.immunoseq.com) single sample analysis of each individual sample was selected, normalized for
PCR bias, (all data analysis included this normalization) and visualized as a 3-D histogram. Upon
exportation of data, graphs were generated for each individual VJ gene for each patient at each
timepoint. This data set was used to determine clonality as well as fold increase over that of donor for
each individual VJ recombination of interest at a later point in analysis.

Identification of GVHD-associated T cells based on clonality of TCR VJ gene recombination
rather than the frequency of TCR Vβ family at each timepoint
In previous analysis in our lab, significant clones were selected by increases in the expression of
TCR Vβ family in recipient over those in respective donor using qRT-PCR technique, which may have
far- reaching implications in terms of the ability to uncover all critical clones.10 TCR Vβ families
include not only all variations of a particular V gene for that family, but also all 13 J gene combinations
with each V gene. So while allowing for a great overall depiction of increase within a Vβ family, this
type of analysis does not pinpoint particular VJ combinations that are relevant. Addressing only
increases by Vβ family results in overlooking relevant clones at a molecular level (VDJ recombinations)
due to high counts of some irrelevant VDJ recombinations which may mask disease-associated clones
within Vβ families. Focusing on clonality of VJ recombination by taking a more fine- tuned approach
using high throughput sequencing technology, on the other hand, will uncover all relevant T cell clones
that are reacting with target antigens. As demonstrated in Figure 3, there are Vβ families such as Vβ
families 4 and 13 in patient 9 that increase while overshadowing other individual VDJ recombinations

21

that may also be relevant. This occurs when proliferation of a particular Vβ family is so large that a
graph depicting fold increase makes that particular family stand out while neglecting to include those
clones that could be relevant due to mono- or oligo-clonality compared to that of donor. Therefore, by
addressing only Vβ families, many individual VJ recombinations that have a massive increase from
donor in addition to clonality are still potentially overshadowed and excluded from further examination.
In addition, while there may be Vβ families that do not increase from that of donor, increase of
particular VJ clones within that Vβ family are detectable at a molecular level. As demonstrated in
patient 9, although there is no fold increase (decimal points as fold-increase data on Y-axis indicate a
decrease from donor) from the donor of the Vβ families 10 and 14 (Figure 3), there is clonality (Figure
4) and increases of clones within that family from that of donor (Figure 5). Only exploration of clones at
a molecular level could uncover these seemingly small fluctuations in particular TCR Vβ’s that could be
critical in disease manifestation. This is why clonality was addressed prior to that of fold increase over
donor in this study. By selecting clones based on clonality first, we automatically exclude those clones
that are increased as a result of homeostatic proliferation and leave only antigen- reactive clones.

Revealing proportions of donor- derived stem cells and T cells
Upon uncovering those clones that were both clonal and followed a trend in clonality that
correlated with GVHD progression, the sequences were broken down at a molecular level into those
clones that were expressed in both donor and recipient (shared clones derived from the expansion of
donor’s T cells) at any timepoint and those that were expressed in only the recipient (unique clones
derived from new TCR recombination of donor’s stem cells). This division was conducted based on the
knowledge that at full chimerism in recipient, any T cell that is not shared with donor has been newly
generated from engrafted donor stem cells.
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Before this could be completed, however, the next important step was to determine which
recipient sample timepoint was best suited for a more in- depth analysis. Using the same numbers from
the previous spectratyping analysis, the recipient timepoint with the highest count and full donor T cell
chimerism for the VJ recombination of interest was selected. If selection was on a GVHD patient, only
those timepoints in which clinical manifestation of GVHD was present were considered. This was done
by filtering those files derived from a multiple sample analysis including all sequences in order to
uncover all variations of a VJ recombination at a molecular level. Selecting for “intersection of samples”
in the filtering tab during a multiple sample analysis on the ImmunoSEQ website for the donor sample
and all recipient (R) samples for a particular patient, all sequences expressed in any of the samples are
given. This allowed for the exposure of all sequences that are expressed at any timepoint, as opposed to
only those sequences that are shared at all timepoints (“union” of samples).

Obtaining top 20 donor- derived T cell and stem cell clones
Following division of the select VJ recombinations of interest, fold increase over the donor as
well as frequency of such shared and unique clones was then determined. For those clones that were
unique to recipient (stem cell origin), the top 20 VDJ recombinations were selected from the previously
determined timepoint based on either highest count (patients 3 and 14), full chimerism (patient 4), or the
presence of clinical manifestation of GVHD (always R3 for patient 9 and the timepoint with the highest
count for patient 14). For T cell clones shared between donor and recipient, the top 20 clones that
showed the highest increase from donor at the same timepoint (described above) utilized to derive stemcell top 20 clones were collected as well as frequencies of those top 20 clones.
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Fold increase over that of donor

Figure 3. Changes in the expression of TCR Vβ family in GVHD patient 9 when compared with
respective donor. Fold increases in expression of 30 human TCR Vβ families over respective donor
was analyzed in GVHD patient 9 at the time of GVHD (R3) and after GVHD was resolved (R4).

Vβ Family
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Figure 4. Clonality of TCR Vβ is associated with GVHD. Spectratyping analysis of TCR Vβ 10-1 and
TCR Vβ 14 are shown in donor and respective recipient of GVHD patient 9 at the time of GVHD (R3).
Donor

R3

R4

Count of VJ Recombination

TCR
Vβ
10-1

TCR
Vβ 14

.
J gene
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Figure 5: Top T cell VDJ recombinations over that of respective donor in GVHD patient 9. Upon
in-depth exploration of clonal VJ recombinations at a molecular level, relevant VDJ amino acid
sequences can be uncovered based on fold increase over respective donor.

Fold increase over that of donor

TCR Vβ 10-1 J2-1

TCR Vβ 14 J2-1
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Results

TCR VJ clonality can identify GVHD- associated clones
Previous studies in our lab showed that certain TCR Vβ’s were associated with both GVHD and
GVHD-free survival.10 In order to determine whether these T cell clones may differ at molecular levels
we performed high throughput sequencing of 30 human TCR Vβ’s (52 V gene segments) and 13 J
genes. Single sample analysis of Vβ family normalized for primer bias exported to excel was used to
generate spectratyping data of donors and recipients T cells at different timepoints following HSCT.
From spectratyping analysis, we selected those clones that were mono- or oligo- clonal
associated with clinical manifestations of the disease, GVHD, and compared them to those clones that
were also clonal in GVHD- free patients. As demonstrated in Figure 6, there were four VJ
recombinations (TCR Vβ4-3 J1-1, V7-9 J2-7, V10-1 J2-1, and V14 J2-1) in patient pair 9 and 3 that
were deemed significant based on shared clonality between patients and/ or change in clonality pattern
following GVHD resolution at R4. TCR Vβ4-3 J1-1, V7-9 J2-7, and V14 J2-1 are demonstrations of an
altered clonality pattern in addition to decrease from donor at the R4 timepoint (Figure 6a, b, d), while
TCR Vβ V10-1 J2-1 maintains a similar clonality pattern, though with lower counts at R4 compared to
R3 (Figure 6c). The same procedure was applied to the remaining patient pairs with similar results.
Patient 9 was compared to patient 4, who initially had delayed donor T cell chimerism at the R2
timepoint, which resolved at R3 (Table 3). As shown in Figure 7, three clones (TCR Vβ7-1 J2-1, V7-9,
J2-1, and V14 J2-1) were selected based on the same criteria as mentioned above (shared clonality and
potentially altered patterns of clonality upon GVHD resolution). Within these three clones, V7-9 J2-1,
and V14 J2-1 demonstrate an alteration of clonality pattern upon GVHD resolution (Figure 7b, c) while
TCR Vβ V7-1 J2-1 maintains a similar clonality pattern over time, although with substantial decreases
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in numbers (Figure 7a). A similar trend in clonality alteration is seen in the corresponding GVHD-free
partner within the pair, patient 4 (Figure 7a-c). Clonality pattern is unaltered in TCR Vβ 7-1J2-1 (similar
to patient 9) and V14 J2-1 (as opposed to the change in clonality seen in patient 9) at full donor T cell
chimerism (R3) while a change in the pattern of clonality is seen in V7-9 J2-1 (Figure 7c).
As representative patient pairs, comparative analyses of TCR Vβ with patient 14 (who had
persistent and progressive GVHD until death, see Table 2) were also performed. Patient pair 14 and 4
had four VJ recombinations shared (TCR Vβ 4-1 J 2-7, V6-1 J1-5, V7-9 J2-1, and V11-2 J2-1) (Figure
8) which were all deemed relevant based on shared and skewed clonality. Clones were considered if
they exhibited clonality at any timepoint in the GVHD patient, since GVHD was manifest at all three
timepoints (R2, R3, and R4). In patient 14 in Vβ 4-1 J2-7 (Figure 8a), clonality increased from R3 to
R4, with the pattern of clonality remaining the same, whereas in V11-2 J2-1 (Figure 8d) although the
clonality pattern also remained the same, the numbers of that particular recombination increased
substantially. V6-1 J1-5 does not emerge until R4, and a defined clonality is also not observed until this
timepoint, indicating not only its dominance over other clones later in manifestation but also its potential
relevance at later stages of GVHD (Figure 8b). Finally, V7-9 J2-1 has a similar pattern of clonality
throughout the timepoints, with the pattern growing more clonal as disease progresses (Figure 8c).
To complete analysis of all representative patient pairs, the final pair to be discussed is patient
pair 14 and 3, which had three relevant clones selected based on shared clonality which include V4-1 J27 (Figure 9a), V5-6 J1-1 (Figure 9b) and V7-8 J2-7 (Figure 9c). In both V4-1 J2-7 and V7-8 J2-7 in
patient 14, clonality becomes progressively more defined at each timepoint (Figure 9a and Figure 9c),
which is critical for the maintenance of clinical manifestation of GVHD in a competitive internal
environment. The patterns of clonality also persist in the corresponding GVHD-free patient within the
pair.
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Figure 6. TCR Vβ’s are selected based on clonality and shared status between patients 9 and 3.
Spectratyping analysis of TCR Vβ’s are shown in donor and respective recipients of GVHD patient 9
and GVHD- free patient 3. Analyses were performed three months after HSCT for patient 3 and at the
time of GVHD (R3) and GVHD resolution (R4) for patient 9.
A. Vβ 4-3 J1-1
B. Vβ 7-9 J2-7
C. Vβ 10-1 J2-1
D. Vβ 14 J2-1
ND: Not done
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……………………………………………………..
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Donor

ND

Count of VJ recombination

R2

R3

ND

R4

J gene
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Figure 7. TCR Vβ’s are selected based on clonality and shared status between patients 9 and 4.
Spectratyping analysis of TCR Vβ’s are shown in donor and respective recipients of GVHD patient 9
and GVHD- free patient 4. Analyses were preformed three months after HSCT for patient 4 and at the
time of GVHD (R3) and GVHD resolution (R4) for patient 9.
A. Vβ 7-1 J2-1
B. Vβ 7-9 J2-1
C. Vβ 14 J2-1
ND: Not done
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Figure 8. TCR Vβ’s are selected based on clonality and shared status between patients 14 and 4.
Spectratyping analysis of TCR Vβ’s are shown in donor and respective recipients of GVHD patient 14
and GVHD- free patient 4. Analyses were performed three months after HSCT for patient 4 and at the
time of progressing GVHD (R2, R3, and R4) for patient 14.
A. Vβ 4-1 J2-7
B. Vβ 6-1 J1-5
C. Vβ 7-9 J2-1
D. Vβ 11-2 J2-1

ND: Not done
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Figure 9. TCR Vβ’s are selected based on clonality and shared status between patients 14 and 3.
Spectratyping analysis of TCR Vβ’s are shown in donor and respective recipients of GVHD patient 14
and GVHD- free patient 3. Analyses were performed at three months after HSCT for patient 3 and at the
time of progressing GVHD (R2, R3, and R4) for patient 14.
A. Vβ 4-1 J2-7
B. Vβ 5-6 J1-1
C. Vβ 7-8 J2-7

ND: Not done
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GVHD- related TCR VβJ clonality is not always associated with an increased frequency in
recipient over the donor at the onset of GVHD for all individual VJ recombinations
From each Vβ spectratyping graph, those clones that were both clonal and shared between each
patient pair were selected and examined for change in frequency from donor. If a particular VJ
recombination was found significant in the GVHD patient, the corresponding clone from the GVHDfree patient was also analyzed. In the case of persistent GVHD (patient 14), any of the three timepoints
(R2, R3, R4) was considered for analysis, since GVHD was present in all samples. For patient 9, who
had resolution of GVHD at the R4 timepoint, only clones that were present at R3 and decreased at the
R4 timepoint were considered (the R2 timepoint was eliminated due to low productivity of sequencing).
A decrease at the time of GVHD resolution (timepoint R4) was therefore a criterion for inclusion in
patient 9. Both timepoints were considered for GVHD- free patient 3, and only the timepoint with full
donor T cell chimerism was considered for GVHD-free patient 4 (R3).
Using the same data set that was utilized to create the spectratyping graphs, changes in the
frequency of GVHD-associated clones were determined. This allowed for the determination of alteration
of counts of a particular VJ recombination compared to that of donor. This analysis showed that
clonality in spectratyping did not always translate into an increase from donor at the time of GVHD. For
instance, V7-9 J2-7, V10-1 J2-1, V14 J2-1 (patient 9, Figure 6b-d), V7-9 J2-1 and V14 J2-1 (patient 9,
Figures 7b and c), V4-1 J2-7, V6-1 J1-5, V7-9 J2-1 (patient 14, Figure 8a) and V5-6 J1-1 and V7-8 J2-7
(patient 14, Figure 9c), showed skewed clonality, however, these clones did not increase at the time of
GVHD (R3) while decreased (patient 9) or persisted (patient 14) at the resolution or persistence of
GVHD at R4, respectively (Figures 10a and b). In contrast, all of these clones (Figure 10), except V11-2
J2-1 (Figure 10b, upper right panel), and V4-1 J2-7, and V7-8 J2-7 (Figure 10b, lower right panel)
increased in GVHD-free patients 3 or 4 (Figure 10b).
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In addition, there were also clonal T cells that increased in patients compared to their respective
donors at the time of GVHD (R3) and decreased or persisted at the resolution or persistence of GVHD
(R4), respectively. For instance, V7-1 J2-1 (patient 9, Figure 10a) and V11-2 J2-1 (patient 14, Figure
10b) increased at the time of GVHD (R3) and decreased (patient 9) or remained at high levels (patient
14) at the resolution or persistence of GVHD (R4), respectively (Figures 10a and b). V4-3 J1-1 (patients
9, Figure 10a) increased at R3 but did not show appreciable decrease when GVHD was resolved at R4
(Figure 10a, upper left panel). V4-1 J2-7 also increased at R4 in patient 14 when GVHD persisted but
not at R3 when GVHD appeared (Figure 10b, upper left panel). In contrast, V4-1 J2-7 (in patient 3) and
V11-2 J2-1 (in patient 4) did not increase over the donor in GVHD-free patients (Figure 10b, right
panels). V4-3 J1-1 increased at R2 and decreased one year after HSCT in GVHD-free patient 3 (Figure
10a). Again, these data suggest differences in the trend of frequency of these shared clones in GVHD vs.
GVHD-free patients. These data also suggest that further molecular analysis of TCR Vβ is needed to
determine whether relevant VDJ recombination associated with GVHD may differ from those in
GVHD-free patients.
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Figure 10. Alterations of counts of select VJ recombinations shared between GVHD patients and
GVHD-free patients. Numbers of different VJ recombinations in each clonal population were
determined in GVHD patients 9 (A) and 14 (B) as well as GVHD-free patients 3 and 4.

Number of VJ recombination
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Sample
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TCR Vβs that showed clonality and were shared between patients with GVHD and GVHD- free
patients differ at a molecular level from one another in both amino acid sequence and increase in
expression from donor following HSCT
Similarity in trends of clonality provides the justification for high- throughput analysis in order
to uncover those individual VJ recombinations that are contributors to clinical manifestation of GVHD.
More detail is needed to uncover individual relevant clones that show persistent increase in frequency
associated with both GVHD and GVHD-free status in order to uncover which exact VJ recombinations
are relevant to GVHD. In those clones that were deemed relevant based on shared clonality and trends,
variability existed upon examination at a molecular level of the number of critical clones. In most cases
there were fewer different donor- derived TCR VβJ sequences that had higher frequencies overall.
As discussed above, patient 9 developed GVHD at R3, and GVHD was resolved at R4. This
patient represents responsiveness to the treatment and can be compared with GVHD-free patient 3 (both
had full chimerism) for VDJ molecular analysis to identify unique GVHD-associated VDJ
recombinations based on increase at R3 and decrease at R4. There were also two different conditions in
GVHD patient 9 where some clones did not increase over the donor but decreased upon GVHD
resolution (Vβ14 J2-1, Figure 10a) and some clones increased over the donor but did not decrease
significantly upon GVHD resolution (Vβ4-3 J1-1, Figure 10a). Molecular analyses of these two clones
were performed in order to determine that shared clones associated with GVHD and GVHD-free differ
at molecular levels, i.e. VDJ recombinations, and that changes in the frequency of GVHD-associated
clones may be revealed at the molecular levels. We also performed similar analysis in GVHD patient 14
and GVHD-free patient 4.
Given that donor- derived stem cells contained both T cells and stem cells, the number of
different VDJ sequences for both donor- derived T cells and newly formed T cells from donor stem cells
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in recipient microenvironment was identified by filtering for presence/ absence of each individual
sequence at each timepoint in the recipient. As shown in Figure 11, there were two donor-derived T cell
types in the recipients 3-4 months after HSCT: those expanded from donor T cells (shared T cells shown
in brown color) and those derived from donor stem cells and underwent VDJ recombination in the
recipients (unique T cells shown in blue color). From both the stem cell and the T cell subset, the top
twenty clones were analyzed.
In the analysis of T cell clones that were shared between donor and recipient comparing GVHD
patient 9 and GVHD-free patient 3 (Figure 12a) , both Vβ 4-3 J1-1 and Vβ 14 J2-1 had a limited number
of clones that were significantly higher in terms of fold increase than in their donor counterparts. These
clones were considered to be more relevant than the others in terms of disease manifestation or GVHDfree survival due to their marked size in fold increase from donor compared to the others within the top
twenty. In the case of donor-derived T cell clones (shared sequences between donor and recipient),
GVHD patient 9 showed seven different VDJ sequences in V4-3 J1-1 that demonstrated increases over
respective donor at the time of GVHD whereas GVHD-free patient 3 had a higher diversity of different
V4-3 J1-1 clones (Figure 12a). Importantly, the three V4-3 J1-1 clones that showed 100-400 fold
increases over respective donor in GVHD patient 9 were distinct from the three different V4-3 J1-1
clones that showed 100-900 fold increases in GVHD-free patient 3 over respective donor. Similarly,
three different V14 J2-1 clones that showed 100-900 fold increases in GVHD patient 9 over their
respective donor differed from the three different clones that increased 20-170 folds in GVHD-free
patient 3 over their respective donor. These data confirm that clonality and increases in certain TCR
Vβ’s transferred from respective donors in both GVHD and GVDH-free patients are not indicative of
cross reactivity of T cells with tumor cells and self cells. Rather, distinct T cell clones (VDJ
recombinations) may be associated with reactivity against tumor cells and self cells separately. In order
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to determine whether different VDJ recombinations of these two clones that had highest frequencies in
each patient may be specific to each patient, the top 20 sequences with highest frequencies were also
analyzed of the same shared (T cell derived) VJ recombinations shared between GVHD and GVHD-free
patients (Figure 12b). As shown in Figure 12b, these shared clones with the highest frequencies in each
patient (>0.2% within V4-3 J1-1 and >0.05% within V14 J2-1) did not show any similarity between
GVHD and GVHD-free patients. Frequency of these T cell clones in the recipients are also shown in
Figure 12b in order to demonstrate not only the much higher scales (Y- axis) but also the greater
diversity in frequencies from stem- cell derived T cells (Figure 13).
Differences in minor histocompatibility antigens (mHA) in individuals suggest that newly
recombined T cells following HSCT would be different at molecular levels between GVHD and GVHDfree patients. To test this, top 20 VDJ recombinations that were unique to the recipients 3-4 months after
HSCT but were absent in their respective donors were analyzed. As shown in Figure 13, five different
V4-3 J1-1 clones showed highest frequencies in GVHD patient 9 (over 0.001%) compared to all T cell
recombinations in this patient. On the other hand, only two different clones showed such a high
frequency (over 0.001%) in GVHD-free patient 3. Sequence analysis of these clones showed no
similarity between these higher- frequency clones. Similar observations were made analyzing V14 J2-1
in GVHD patient 9 and GVHD-free patient 3. Similar observations were made comparing GVHD
patient 9 and GVHD-free patient 4 (Figure 14 and 15) as well as the other patient pairs GVHD patient
14 vs. patient 3 and 4 (Figures 16-19).
Few sequences in the selected top twenty VDJ recombinations matched exactly one another
between GVHD and GVHD- free patients. Among these, two sequences were derived from stem cells in
patient pair 4 and 9 (Figure 14- CASSSDYLGPGSSAYNE in V7-1 J2-1 and CASSPSGRGYNE in V14
J2-1). In addition, four sequences derived from donor T cells in patient pair 9 and 3 [one of which is
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shown in Figure 12- CASSQVAFSYNE {V14 J2-1}]), and of those, none from the top relevant
recombinations matched one another. In other words, from those select clones that did, in fact, exactly
match one another in terms of amino acid sequence, both would not be found within the selected top
relevant clones. Only one exception was found between patient pair 9 and 3 V4-3 J1-1 (Figure 12a, first
column) (CASSPSRNTE).
Figure 11. The distribution of all VDJ recombinations derived from transplant, both expanded T
cells and T cells derived from donor stem cells. Log scatter plots plotting distribution of donorderived T cells in recipients 3-4 months after SCT. Brown dots indicate engrafted T cells while X axis
depicts those cells that were newly generated from donor stem cells.
GVHD patient 9

Donor

GVHD- free patient 3

Recipient
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Figure 12. Top VDJ sequences that were shared between donor and GVHD or GVHD-free
recipients differed at molecular levels.
A. Fold increase of top shared sequences of the relevant clones over that of donor in GVHD patient 9
and GVHD-free patient 3 for V4-3 J1-1 and V14 J2-1 at 3-4 months following HSCT
B. Frequency of top shared sequences of the relevant clones in each patient.
A.

Patient 9

Fold increase over that of donor

V4-3 J1-1

V14 J2-1

Patient 3
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Figure 13. Top VDJ sequences that were unique to the recipients differed at molecular levels
between GVHD patient 9 and GVHD-free patient 3. Top Unique Sequences over that of donor in
patient pair 9 and 3 for V10 J2-1 and V14 J2-1 (patient 9 at timepoint R3 and patient 3 at timepoint R2)
Patient 9

Percent frequency among all VDJ sequences

V4-3 J1-1

V14 J2-1

Patient 3

Amino Acid Sequence
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Figure 14. Top VDJ sequences that were shared between donors and recipients differed at
molecular levels between GVHD patient 9 and GVHD-free patient 4. Top shared sequences over
that of donor in patient pair 9 and 4 for V7-1 J2-1 and V14 J2-1 (patient 9 at timepoint R3 and patient 4
at timepoint R3)
Patient 9

Fold increase over that of donor

V7-1 J2-1

V14 J2-1

Patient 4

Amino Acid Sequence
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Figure 15. Top VDJ sequences that were unique to the recipients differed at molecular levels
between GVHD patient 9 and GVHD-free patient 4. Top Unique Sequences over that of donor in
patient pair 9 and 4 for V7-1 J2-1 and V14 J2-1 (patient 9 at timepoint R3 and patient 4 at timepoint R3)
Patient 9

Percent frequency among all VDJ recombinations

V7-1 J2-1

V14 J2-1

Patient 4

Amino Acid Sequence
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Figure 16. Top VDJ sequences that were shared between donors and recipients differed at
molecular levels between GVHD patient 14 and GVHD-free patient 4. Top shared sequences over
that of donor in patient pair 14 and 4 for V4-1 J2-7 and V6-1 J1-5 (patient 14 at timepoint R4 and
patient 4 at timepoint R3)
Patient 14

Fold increase over that of donor

V4-1 J2-7

V6-1 J1-5

Patient 4
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Percent frequency among all VDJ recombinations

Figure 17. Top VDJ sequences that were unique to the recipients differed at molecular levels
between GVHD patient 14 and GVHD-free patient 4. Top unique Sequences over that of donor in
patient pair 14 and 4 for V4-1 J2-7 and V6-1 J1-5 (patient 14 at timepoint R4 and patient 4 at timepoint
R3)
Patient 14
V4-1 J2-7
V6-1 J1-5
.

….
Patient 4

…..
Amino Acid Sequence
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Fold increase over that of donor

Figure 18. Top VDJ sequences that were shared between donors and recipients differed at
molecular levels between GVHD patient 14 and GVHD-free patient 3. Top shared sequences over
that of donor in patient pair 14 and 3 for V4-1 J2-7 and V5-6 J1-1 (patient 14 at timepoint R4 and
patient 3 at timepoint R2)
Patient 14
V4-1 J2-7
V5-6 J1-1

Patient 3

Amino Acid Sequence
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Percent frequency among all VDJ recombinations

Figure 19. Top VDJ sequences that were unique to the recipients differed at molecular levels
between GVHD patient 14 and GVHD-free patient 3. Top unique Sequences over that of donor in
patient pair 14 and 3 for V4-1 J2-7 and V5-6 J1-1 (patient 14 at timepoint R4 and patient 3 at timepoint
R2)
Patient 14
V4-1 J2-7
V5-6 J1-1

Patient 3

Amino Acid Sequence
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T cell clones associated with both GVHD and GVHD-free survival fail to show an association
between donor-derived T cells or stem cells with disease outcome
In order to determine whether donor- derived T cells (sequences shared between donor and
recipient) or stem cells (sequences unique to recipient) may predict GVHD, those clones previously
selected for relevance based on common spectratyping trends were analyzed. The same patient pairs as
described above were used here in order to create a comparison between patients with GVHD and those
with GVHD- free survival. In this case, a comparative analysis was conducted between GVHD patients
9 or 14 and GVHD- free patients 3 or 4 at the same relevant timepoint as utilized in previous analysis
above. Our hypothesis was that ratios of the stem cell- derived T cells and the engrafted donor T cells
could provide prognostic value in determining the outcome of disease. Figures 20a-d demonstrates
numbers of unique T cells derived from donor’s stem cells and numbers of donor’s T cells expanded in
the recipients at different timepoints following HSCT. Counts were divided based on when they were
present in the samples ie, if the amino acid sequence was present at R3 only, R4 only, or both R3 and R4
for stem cell- derived T cells (unique) or if the sample was shared between donor at only the R3
timepoint or both the R3 and the R4 timepoint for donor- derived T cells (shared). The number of
different stem cell- derived T cells (unique) was greater than that of shared for every relevant VJ
recombination examined with only two exceptions in V4-3 J1-1 in GVHD-free patient 3 (Figure 20a)
and V7-1 J2-1 in GVHD patient 9, (Figure 20 b). There was no consistent association between number
of unique or shared T cells for all the relevant clones with trend of GVHD in patients 9 or 14.
The ratio of unique to shared T cells in GVHD patients was then calculated for each timepoint in
order to determine whether such analysis may predict disease outcome. As shown in Figure 21, although
ratios of unique to shared T cell clones were higher in GVHD compared to GVHD-free patients in
patient pairs 9 vs. 3 and patient 14 vs. 3, such correlation did not exist while comparing patient pair 9 vs.
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4 or patient 14 vs. 4. Patient 3, but not patient 4, had consistently smaller ratios regardless of which
GVHD patient they are being analyzed alongside of (Figure 16).
Frequency of each relevant clone in patients was then determined. Overall frequency refers to
the percentage of that particular amino acid sequence within the entire 30 different TCR Vβ families at
each timepoint for that patient (R2, R3, R4). Table 5 provides scales of percent frequencies of relevant
sequences derived from stem cell (unique) or T cell (shared) data for the patient pairs selected for
analysis. Donor-derived T cells were much higher in most analyzed VJ recombinations, so that at a
numerical value, there were a greater overall number of T cells and a more diverse array of stem- cell
derived T cells. For example, in the first row of Table 5a, addressing Vβ 4-3 J1-1, the frequency of that
VDJ recombination is higher in the shared population (1.7 and 1.4% of total VDJ recombinations) than
that of the unique population (0.009 and 0.004%), though these frequencies did not distinguish GVHD
patient 9 from GVHD-free patient 3. In addition, V7-9 J2-7 had the highest frequency of unique clones
whereas V-3 J1-1 had the highest frequency of shared clones in GVHD- free patient 3 which distinguish
this patient from GVHD patient 9 (Table 5a). However, frequency of unique or shared clones did not
show a consistent association with GVHD status. Similar observations were made comparing different
patient pairs (Table 5b-d).
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Figure 20. Distribution of donor- derived unique and shared T cell subsets fail to show correlation
with the trend of GVHD. Number of different VDJ recombination of relevant T cell clones derived
from donor stem cells (unique) or donor T cells (shared with D) at different timepoints following HSCT
(R2, R3, R4) in patient pairs 9 vs. 3 (A), 9 vs. 4 (B), 14 vs. 3 (C) and 14 vs. 4 (D).
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Figure 21. Relevant T cell clones associated with both GVHD and GVHD-free patients do not
show a correlation with the ratio of unique to shared T cell subsets. Ratios of unique to shared T cell
clones for relevant sequences were analyzed for patients 9 vs. 4 (A), 9 vs. 3 (B), 14 vs. 3 (C) and 14 vs.
4 (D).
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Table 5. Relevant T cell clones associated with both GVHD and GVHD-free patients do not show a
correlation with the frequency of unique to shared T cell subsets. Frequencies indicate the
percentage of the most abundant VDJ sequences within all 30 TCR Vβ’s in the entirety of samples
examined for patients 9 vs. 3 (A), 9 vs. 4 (B), 14 vs. 4 (C) and 14 vs. 3 (D). Highest frequencies were
shown in bold.

A.

VJ
recombination

highest frequency of unique
clones
Patient 9
Patient 3

highest frequency of shared clones
Patient 9

Patient 3

V4-3 J1-1

0.009

0.004

1.7

1.4

V7-9 J2-7

0.004

0.18

0.6

0.9

V10-1 J2-1

0.03

0.035

0.2

0.07

V14 J2-1

0. 05

0.03

0.2

1.2

B.

VJ
recombination

highest frequency of unique
clones
Patient 9
Patient 4

highest frequency of shared clones
Patient 9

Patient 4

V7-1 J2-1

7 x 10-4

0.09

8.2

2 x 10-5

V7-9 J2-1

0.009

0.012

0.7

2.6

V14 J2-1

0. 05

0.3

0.2

0.01
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C.

VJ
recombination

highest frequency of unique
clones
Patient 14
Patient 4

highest frequency of shared clones
Patient 14

Patient 4

V4-1 J2-7

0.2

0.2

0.007

0.002

V6-1 J1-5

0.35

0.2

0.003

0.002

V7-9 J2-1

8x 10-5

0.012

0.03

2.6

V11-2 J2-1

0.004

0.025

4.5

0.008

D.

VJ
recombination

highest frequency of unique
clones
Patient 14
Patient 3

highest frequency of shared clones
Patient 14

Patient 3

V4-1 J2-7

0.2

0.0018

0.007

0.04

V5-6 J1-1

0.004

0.6

0.25

9 X 10-4

V7-8 J2-7

0.0025

8 x 10-4

0.1

0.02
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GVHD- specific T cell clones revealed an association between frequency of unique T cells and
likelihood of GVHD recovery
In contrast to the method of analysis discussed in the previous section that addressed shared
clones between GVHD and GVHD-free patients, further analysis was conducted to uncover those clones
that were specific to GVHD patients only. GVHD-specific clones were identified based on their skewed
clonality in GVHD patients but not in GVHD-free patients. Figure 22 shows representative T cell clones
based on this criterion and shows that trends of clonality in GVHD patients were different from those in
GVHD-free patients. An additional filtering performed to focus on clones that were declined at the time
of GVHD resolution in patient 9 (Figure 23a) and persisted or increased with the persistent of GVHD in
patient 14 (Figure 23b). There were seven different clones in patient 9 and eight different clones in
patient 14 which were associated with the trend of GVHD in these patients, i.e., all the clones increased
over the respective donors at the time of GVHD (R3) and then either decreased or persisted at R4 in
patient 9 and patient 14, respectively (Figure 23).
Following the selection of representative T cell clones associated with GVHD, division into T
cell originated from donor T cells (shared T cells) and those originated from donor stem cell (unique T
cells) subsets was conducted and the top 20 VDJ sequences from each subset were derived. Three
representative clones from both GVHD patients (9 and 14) that were not shared with either GVHD- free
patients (3 or 4) were therefore selected based on both highest counts and highest fold increase from
donor and subjected to analysis of numbers of unique and shared T cell clone ratios (Figure 24). Ratio
of unique to shared T cell clones (Table 6) and frequency of unique and shared T cell clones relative to
all VDJ recombinations in each patient (Table 7) were then determined. In GVHD patient 9, Vβ 25-1 J16, Vβ 25-1 J2-2 and Vβ 27 J1-1 were selected based on both highest counts and largest decrease upon
GVHD resolution at the R4 timepoint as shown in Figure 23a. The same procedure was conducted for
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GVHD patient 14, with the difference being that increase or persistence, as opposed to decrease, of the
selected clones was critical since GVHD persisted for all timepoints in that particular patient. Based on
these criteria, Vβ 5-4 J2-2, Vβ 5-4 J2-7, and Vβ 12-5 J2-7 were selected for a more in-depth analysis of
GVHD- specific clones in patient 14. An outlier was Vβ 6-9 J2-2, which was not increased from donor
at R3, but showed substantial increase at R4, indicating its potential relevance in resistance to treatment
at R4 (Figure 18b). Vβ 5-4 J2-2, Vβ 5-4 J2-7, and Vβ 12-5 J2-7 were therefore the clones selected from
that group which fit all three criteria of unshared status with GVHD- free patients, and increase from
donor with persistence (or increase) throughout all timepoints.
As shown in Figure 24, the number of unique VDJ clones was always greater than shared VDJ
clones in both GVHD patients 9 and 14. It was uncovered that ratio of unique to shared T cells was
associated with the trend of GVHD. As shown in Table 6, upon resolution of GVHD in patient 9, the
ratio of unique to shared T cells was reduced (Table 6a), while maintained at high levels in patient 14,
whose GVHD persisted until death (Table 6b). As an example, for Vβ 25 J1-6 in Table 6a, which
depicts the ratios for patient 9 between timepoint R3, and timepoint R4, all are reduced at R4, indicating
a reduction in stem-cell derived T cells at that timepoint, since the number of shared T cell clones is
zero. Patient 14, on the other hand, had persistent GVHD, and their stem cell – to- T cell ratio increased
as GVHD progressed (from R3 to R4), which is indicated on Table 6b. The only exception in patient 14
was Vβ6-9 J2-2 that did not maintain high ratio of unique to shared T cells at R4 compared to R3 (Table
6b), because this clone emerged at R4 and it was absent at R3 (Figure 23b). This may suggest that
emergence of new clones at R4 in addition to the persistence of GVHD-associated clones at R3 and R4
may cause resistance to therapy for GVHD in patient 14.
However, numbers of unique or shared T cell clones indicates their diversity rather than their
direct involvement in GVHD reactivity. To determine whether unique or shared T cells may be involved
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in GVHD, frequency or abundance of these clones were determined in patients 9 and 14. As shown in
Table 7a, frequency of all three shared clones (second and third columns) was smaller than unique
clones (fourth and fifth columns) in patient 9 who responded to treatment and resolved GVHD at R4. In
addition, frequency of such unique clones that emerged at R4 was also smaller than those at R3 (fourth
and fifth columns, Table 7a). On the other hand, patient 14 who showed persistent GVHD had higher
frequency of shared T cell clones (second and third column, Table 7b) than unique clones (fourth and
fifth columns, Table 7b). In addition, number of new T cell clones emerged at R4 remained high
compared to shared clones that were only present at R3 (fourth and fifth columns, Table 7b). In addition,
frequency of unique clones decreased at R4, when GVHD was resolved in patient 9 (Table 7a) whereas
both shared and unique T cell clones increased with the persistence of GVHD at R4 in patient 14 (Table
7b). Clones that were unique and shared between donor and recipient at both R3 and R4 were also
analyzed. It was found that clones at both timepoints in patient 9 follow a similar trend in that the
frequency of clones decreases at R4 when GVHD resolves (Table 7c). On the other hand, there was no
discernible trend in those clones at both timepoints for patient 14, in which some frequencies increased,
some decreased and some remained the same from R3 to R4 (Table 7d). These data suggest that
although both unique and shared T cells may be involved in GVHD, persistence of GVHD in patient 14
may be determined by high frequency of shared T cells whereas high frequency of unique T cell clones
may predict a good prognosis for GVHD therapy.
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Figure 22. GVHD- specific TCR Vβ’s show distinct clonality compared to GVHD-free patients.
GVHD-specific clones were identified by comparative analysis of VJ recombinations in patients 9 vs. 4
and 3 for Vβ 25 J1-6 & Vβ 25 J2-2 (A) or Vβ 27 J1-1 (B), and in patients 14 vs. 4 and 3 for Vβ 5-4 J2-2
& Vβ 5-4 J2-7 (C) or Vβ 12-5 J2-7 (D).
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Figure 23. Certain GVHD- specific VJ recombinations are associated with the trend of GVHD.
Fold increases of relevant GVHD-specific T cell clones over the respective donors at R3 and R4
timepoints were analyzed for GVHD patient 9 (A) and patient 14 (B).
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VJ recombination
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Figure 24. Distribution of donor-derived unique and shared T cell subsets show a correlation with
the trend of GVHD. Number of different VDJ recombinations of relevant T cell clones derived from
donor stem cells (unique) or donor T cells (shared with D) at different timepoints following HSCT (R2,
R3, R4) in GVHD patients 9 and 14.
Patient 14

Number of different VJ recombinations

Patient 9
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Table 6. The ratio of unique to shared GVHD- specific T cell clones is decreased upon GVHD
resolution and increased during GVHD progression. Ratios of unique to shared T cell clones for
relevant VDJ sequences were analyzed for GVHD patient 9 (A) and patient 14 (B).
A.
VJ
recombination

Unique to
shared
ratio (at R3
only)

Unique to
shared
ratio (at R4
only)

V25 J1-6

8:0

3:0

V25 J2-2

10:1

4:0

V27 J1-1

37:0

20:0

VJ
recombination

Unique to
shared
ratio (at R3
only)

Unique to
shared
ratio (at R4
only)

V5-4 J2-2

209:47

131:9

V5-4 J2-7

259:68

214:11

V12-5 J2-7

4:1

18:0

V6-9 J2-2

5:0

1:0

B.
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Table 7. The frequency of unique and shared GVHD-specific T cell clones is decreased upon
GVHD resolution and increased during GVHD progression. Scale of frequencies indicate the
percentage of the most abundant unique and shared VDJ sequences that were present at R3 or R4
timepoints for patient 9 (A) and patient 14 (B) or were present at both R3 and R4 timepoints for patient
9 (C) and patient 14 (D).
A.

VJ
recombination

Highest
scale
shared
(R3)

Highest
scale
shared
(R4)

Highest
scale
unique
(R3)

Highest
scale
unique
(R4)

V25 J1-6

0

0

0.0025

1.8 x 10-4

V25 J2-2

1.4 x 10-4

0

0.009

0.002

V27 J1-1

0

0

0.035

0.02

B.
VJ
recombination

Highest
scale
shared
(R3)

Highest
scale
shared
(R4)

Highest
scale
unique
(R3)

Highest
scale
unique
(R4)

V5-4 J2-2

2.7

4

0.005

0.014

V5-4 J2-7

1

1.8

0.002

0.018

V12-5 J2-7

4.5 x 10-4

0

4.5 x 10-4

0.0045
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C.
VJ
recombination

Highest
scale
shared
(R3)

Highest
scale
shared
(R4)

Highest
scale
unique
(R3)

Highest
scale
unique
(R4)

V25 J1-6

0.013

0.003

0.002

1.8 x 10-4

V25 J2-2

1.3 x10-4

1.1 x10-4

0.008

0.001

V27 J1-1

0.45

0.11

0.03

0.006

VJ
recombination

Highest
scale
shared
(R3)

Highest
scale
shared
(R4)

Highest
scale
unique
(R3)

Highest
scale
unique
(R4)

V5-4 J2-2

0.01

0.009

0.005

0.005

V5-4 J2-7

0.009

0.002

0.003

0.002

V12-5 J2-7

0.001

4.2 x10-4

0

0

D.
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Discussion

We performed a pilot study in patients with hematologic malignancies who received allogeneic
stem cell transplantation in order to determine the molecular basis of T cell-mediated GVHD. Four
patients were selected among 13 patients (5 GVHD-free and 8 with GVHD, Table 1) representing mild
GVHD that was resolved following treatment (patient 9, Table 2); severe GVHD that was resistant to
therapy (patient 14, Table 2) as well as two patients with full donor T cell chimerism (patient 3, Table 3)
or mixed donor T cell chimerism (patient 4, Table 3) who remained GVHD-free and relapse-free over
one year after HSCT. We showed that skewed clonality and usage frequency of TCR VβJ compared to
respective donors can indicate tissue- reactivity of T cells that cause either GVHD or result in GVHDfree survival, perhaps as a result of the elimination of residual tumor cells. Our data also suggest that
despite certain shared VJ recombinations between patients with GVHD and patients that are GVHDfree, there are differences between the VDJ recombinations in the two subsets of patients at a molecular
level that distinguish them from one another. Finally, the ratio and frequency of unique to shared T cells
that were associated with both GVHD and GVHD-free survival failed to demonstrate a discernible
difference between the two patient subsets. In contrast, such ratio and frequency patterns predicted
disease outcome when GVHD-specific clones that were unshared with GVHD-free patients were
analyzed. In fact, the ratio of unique to shared T cell clones that increased over their respective donors at
GVHD onset persisted or decreased as GVHD progressed or resolved, respectively. In addition, high
frequencies of donor-derived T cells (shared T cell clones) in GVHD patients were associated with
disease outcome, suggesting that while ratio of unique to shared T cell clones may predict the trend of
the disease, frequency of the shared T cell subset may be a critical component in predicting severity of
disease in addition to responsiveness to treatment. In brief, analysis of shared and unique T cell clones
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suggest that while both T cell and stem cell components of transplant are involved in GVHD reactivity,
high frequency of the T cell component is associated with poor prognosis whereas high frequency of
stem cell component may predict good prognosis for the treatment of GVHD.
The benefit of isolation of T cell mRNA (as opposed to DNA) in our analyses is that it gives a
snapshot of what proteins may be translated in the recipient and donor microenvironment. In this context
it is exposing those T cell clones that may be active at the various timepoints during the GVHD disease
progression. The selective proliferation of T cells is a result of antigen-specific induction, and during a
graft-versus-host response with no other co-morbidities, it can be reasonably assumed that the antigen
that is inducing the expansion of a particular VDJ recombination is host tumor tissue.18 From this
induction, those T cell clones that are experiencing specific clonal expansion provide critical
information about particular VDJ recombinations in T cells indicative of disease.
Of the four patients analyzed, all but one (patient 4) had nearly full donor T cell chimerism at all
timepoints. Patterns of clonality are altered significantly from R2 to R3 in many of the selected clones in
patient 4. Changes in the pattern of clonality in patient 4 from the R2 timepoint to the R3 timepoint have
the potential to be indicative of the mixed chimerism at the R2 timepoint. The observation that none of
the eight GVHD patients studied as opposed to 4 out of 5 of the GVHD-free patients had donor T cell
chimerism of above 10% at any time (Table 3) supports observations that mixed chimerism is critical for
tolerance induction.45 Self- tolerance, while decreasing the likelihood of GVHD, may also reduce
GVT.46 However, expression of tumor-specific mHA can result in GVT effects without GVHD, as
shown in this study. In addition, mixed chimeras have been found to produce less effector T cells, which
could be demonstrated in the observation that 4 of the 5 patients who were GVHD-free had mixed
chimerism at some point.46
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TCR Vβ’s that are shared between patients with GVHD and GVHD-free survival differ from one
another at a molecular (VDJ sequence) level
Our first hypothesis that clones of which their expression is upregulated in recipients compared to
donor in both subsets of patients (GVHD and GVHD- free), the TCR Vβ will differ at a molecular level
between the two subsets due to differences in mHAs was supported by molecular analysis of VDJ
recombinations of TCR Vβ. The select VJ recombinations chosen based on shared clonality patterns
between GVHD and GVHD-free patients were examined on a molecular level of the top VDJ sequences
of relevant clones expressed in the given VJ recombination. Those engrafted and expanded T cells from
donor have already completed development, and only variances in the D region, which was taken into
account in the molecular analysis of VDJ sequences, can account for the variability between the two
groups. On the other hand, since newly formed T cells develop in the recipient microenvironment from
donor stem cells, they have an additional level of complexity that can allow for differences in the CDR3
region. During the development and subsequent recombination of the V, D, and J regions, these T cells
also acquire random nucleotide insertions at each junction point, leading to another layer of diversity in
this T cell subset.
One of the primary complications of attempts to eradicate tumors using immune system cells is that
many antigens that are expressed on tumors are also shared ubiquitously with healthy host tissue.8 From
all of the uncovered high-frequency relevant sequences within each shared (originated from donor T
cells) and unique (originated form donor stem cells) subsets, one sequence was found that was shared (a
donor-derived sequence in V4-3 J1-1) between GVHD patient 9 and GVHD-free patient 3 (Figure 12).
Both patients 9 and 3 had NHL, and neither relapsed from their disease following treatment, which
could indicate that this shared sequence may be specific to tumor. This single shared sequence out of
many top sequences coincides with evidence that dictates that while there are many antigens that have
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the potential to be recognized during GVHD and GVT, a select few of those antigens are expressed
solely on tumor. Distinct molecular signatures (VDJ recombinations) of certain TCR Vβ that were
associated with both GVHD and GVHD-free survival also suggest distinct antigenic profiles between
tumor cells and self cells. Therefore, this VDJ sequence shared between two patients with the same
disease who recovered from said disease following treatment could express tumor associated antigens
(TAAs) and a TCR specific to that antigen following HSCT.8
The diversity of polymorphisms in the entirety of the human population would lead to the reasonable
assumption that there is a nearly endless supply of host antigens that can initiate a response in donor T
cells. This fact coincides with the observation that there was great diversity in Vβ families that were
clonal in GVHD patients, as GVHD induces the proliferation of specific T cells and our observations
that there were few shared VDJ sequences between GVHD and GVHD-free patients.11 Therefore, the
observation that few shared clones existed between patients supports data that confirm the ubiquitous
expression of a variety of polymorphic mHA’s capable of initiating a response in donor T cells upon
engraftment.

Both ratio and frequency of GVHD-specific shared and unique T cells provide information about
progression and severity of GVHD
Our second hypothesis that both T cells and stem cells are involved in GVHD such that severity of
GVHD is determined by T cell rather than stem cell component of transplant is supported by our data
showing that the ratio of unique to shared T cells was associated with trend of GVHD such that this ratio
dropped upon GVHD resolution and remained unchanged or increased when GVHD persisted.
Importantly, it was the frequency of shared T cells that were expanded from T cell component of
transplant that predicted poor prognosis for the treatment of GVHD. In fact, patient 9, whose GVHD
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was resolved, showed higher frequency of unique T cells whereas patient 14 whose GVHD persisted
showed higher frequency of shared T cells (Table 7).
Donor T cells undergo selection in the donor microenvironment and upon exposure to host tissue
following engraftment, donor T cells recognize it as foreign since positive and negative selections have
already occurred outside of the host microenvironment.5 In contrast, donor stem cells can undergo
positive and negative selections in the recipient's microenvironment and generate unique mature T cells
that were absent in the donor. Such T cell maturation can take place in the extrathymic niche in adults.
31,35

Therefore, high affinity tissue- reactive unique clones may be eliminated, leaving those that still

have the potential for weak reactivity. This would explain the observation that severity of disease is
correlated with the T cell rather than the stem cell- derived population.
A query that arises from these conclusions stems from the observation that in older adults, such as
those in this study, the thymus should be quite atrophied, with very limited potential for T cell renewal
from naïve T cells.21,22 This begs the question that if the thymus should be mostly inactive, T cell
replenishment should be almost entirely from peripheral expansion.24 How are new T cells being
generated? Studies demonstrate that by the age of 60, the ability of the thymus to regenerate T cells from
stem cells is minimal in patients undergoing non-myoablative conditioning for HSCT.21,26 The average
age of the GVHD patients in our study was 59, and the average age of GVHD-free patients was 54. The
average age of the two studied GVHD patients (patients 9 and 14) was 56 and the average age of the two
studied GVHD free patients (3 and 4) was a mere 45. Within the age limitations of our study, the
thymuses of these patients may still be capable of reconstituting immune cells following transplant.21,26
Secondly, hematopoietic peripheral expansion (HPE) makes a larger and more significant contribution
to immune reconstitution in the thymectomized host than in euthymic host, meaning that in a state of
thymic damage, the likelihood of extrathymic ability to recover T cell population actually increases.21
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Extrathymic selection has been observed in the small intestine and lymph nodes of thymectomized mice,
as well as in the tonsil of adult humans, and is a potential additional route of selection in GVHD patients
with atrophied thymuses.2,31,36,38,39. These data support the potential for extrathymic selection to be an
alternative source of T cells for patients with reduced thymic capacity, as in those undergoing
HSCT.31,38
In patient 14, who had progressive GVHD until death, unique newly emerging clones could
contribute to severity of GVHD. Emergence of new clones may explain resistance to treatment, and is
demonstrated by fluctuations in frequencies of GVHD-specific VDJ sequences that are found at both R3
and R4 (Table 7). Those combinations that were reduced in frequency could represent a response to
treatment, leaving room for the expansion of those clones that were resistant to treatment (those whose
frequencies increased as GHVD progressed). Ratio of unique to shared T cell clones was always
associated with the trend of GVHD. The only outlier in GVHD patient 14, V6-9 J2-2, that did not follow
such a trend suggest the emergence of new clones that are resistant to treatment. Clones for this VJ
recombination showed very low overall frequencies at R3 (5-2 total clones were detected within the
entire Vβ repertoire for individual VDJ sequences) while the frequencies for the single VDJ clone that
emerged at R4 were substantially higher, approximately a 42-fold increase from the highest clones in
either donor or R3, attributes to its relevance.
In general, the number of unique clones was higher than that of shared T cells. In contrast, the
overall frequency of shared T cell clones within the entire Vβ population for a patient was greater. This
was an overarching theme in both GVHD and GVHD-free patients. Higher overall frequencies from the
T cell versus the stem cell subset confirm the observation that although stem cells produce a more
diverse array of sequences, their tissue- associated proliferation rates are consistently lower than their
donor- derived T cell counterparts. This is consistent with data that indicate that thymic reconstitution of
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T cells results in a polyclonal, diverse array of T cells following a lymphodepletive treatment that
substantially reduces T cell diversity.5,25
How can the unique subset be readily defined as from donor- derived stem cells? At most of the
timepoints studied (R3 for patient 4, R2 for patient 3, R3 and R4 for patient 14 and R3 and R4 for
patient 9) donor T cell chimerism was not 100%. In a healthy environment, T cell reconstitution from
stem cells should result in a Gaussian distribution in a spectratype, which none of the relevant clones
considered for analysis had. 21 However, a skewed spectratype would be expected in patients during an
antigen- specific response. Since the GVHD- free patients in this study did not relapse, it can be
assumed that GVT was occurring. Therefore, all 13 patients were either experiencing clinical
manifestation of GVHD or GVT, and in fact were all experiencing an antigen- driven response of some
kind. This lends to the fact that regardless of incomplete chimerism, the stem cell subset can still be
donor derived and demonstrate a skewed spectratype graph. Another important conclusion is that
transplant regimens reduce host naïve T cell populations by about 95%, making it even more likely that
unique T cells are donor derived as opposed to latent recipient cells.25
The high diversity of unique clones is supported by studies that indicate that generation of novel
VDJ recombinations tends to result in a diverse and polyclonal repertoire of T cells due to the random
nucleotide insertions associated with T cell generation.11,12,21 The observation that there are a greater
number of different unique clones contributing to GVHD coincides with the fact that there will be a
more diverse population due to the high number of various polymorphic antigens that are presented to
the emerging T cells upon engraftment into host. This results in a high number of recipient antigens
recognized by donor stem cells, as opposed to the smaller number of different TAAs recognized by
donor cells. 8 In addition, since there are few tumor- specific antigens within the large population of
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potential mHAs within the host, the observation that a diverse group of TCR Vβ’s would be involved in
GVHD, and much less diverse in GVT is justified.39
Since a patient undergoing HSCT has been pre-treated with anti-thymocyte antibodies, they will
have a diminished or entirely depleted T cell population, leaving ample room for a donor population to
expand.6,11 This is designed so that those clones that are engrafted into host will receive a substantial
proportion of proliferative cytokines and be the most likely to expand. Therefore, the higher the number
of a VDJ recombination, the larger its population will be following engraftment. In addition, those
clones that recognize antigen will also consume homeostatic proliferative cytokines and expand as well.5
Since shared sequences are those that engraft into recipient, they already have an advantage in terms of
proliferation and completion for cytokines over newly developing T cells from donor cells and
proliferation will happen more readily and to a greater degree initially upon engraftment in those VDJ
recombinations that have already been established. This “head start” will make actual counts of shared
sequences higher, even though the unique sequences are more diverse.
In conclusion, our finding through this pilot study can guide molecular analysis of TCR Vβ in
large cohorts of patients in order to determine molecular features of GVHD and GVT following
allogeneic HSCT. These data suggest that allogeneic HSCT may be improved by optimizing the proportion
of T cells to stem cells in the transplant as well as developing targeted therapy against GVHD-associated T
cell clones while rescuing GVT-associated T cell clones.

Future directions
An algorithm needs to be developed by application of the proposed analysis to a larger cohort of
patients in order to predict prognosis of allogeneic HSCT. We are to develop a statistical model to
further validate our findings by analyzing five GVHD-free and eight GVHD patients that were included
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in this study. Further research could also optimize T cell to stem cell ratio in the transplant in order to
achieve GVT effects without GVHD complications. Molecular targeted therapy for GVHD should also
be investigated based on the identification of GVHD-associated VDJ recombinations.
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